Amyloidosis Stocks List

Amyloidosis Stocks Recent News

Date Stock Title
May 9 ALZN Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
May 9 IONS The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 9 NTLA Intellia Therapeutics GAAP EPS of -$1.12 beats by $0.25, revenue of $28.94M beats by $19.87M
May 9 NTLA Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 8 ABOS Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 8 IONS Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
May 8 NTLA Intellia Therapeutics Q1 2024 Earnings Preview
May 8 IONS Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
May 8 ABOS Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 8 IONS Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 8 IONS Q1 2024 Ionis Pharmaceuticals Inc Earnings Call
May 8 IONS Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...
May 7 IONS Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
May 7 ABOS Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 7 IONS Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 7 ALZN Alzamend Neuro terminates at-the-market equity offering program
May 7 IONS Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
May 7 ALZN Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
May 7 ALNY Alnylam Issues 2023 Corporate Responsibility Report
May 7 IONS Ionis Pharmaceuticals GAAP EPS of -$0.98 beats by $0.09, revenue of $119M misses by $17.41M
Amyloidosis

Amyloidosis is a disease in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several types with varying symptoms; signs and symptoms may include diarrhea, weight loss, feeling tired, enlargement of the tongue, bleeding, numbness, feeling faint with standing, swelling of the legs, or enlargement of the spleen.There are about 30 different types of amyloidosis, each due to a specific protein misfolding. Some are genetic while others are acquired. They are grouped into localized forms, and systemic ones. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and familial amyloid polyneuropathy).Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about 1 per 1,000 people die from amyloidosis. Amyloidosis has been described since at least 1639.

Browse All Tags